IMMUNEX CORP /DE/
S-3, EX-5.1, 2000-08-09
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: IMMUNEX CORP /DE/, S-3, EX-3.2, 2000-08-09
Next: IMMUNEX CORP /DE/, S-3, EX-23.1, 2000-08-09



<PAGE>

                [ORRICK, HERRINGTON & SUTCLIFFE LLP LETTERHEAD]

                                                                     EXHIBIT 5.1

                                August 8, 2000

Immunex Corporation
51 University Street
Seattle, Washington 98101

          Re:  Immunex Corporation
               Registration Statement on Form S-3
               ----------------------------------

Ladies and Gentlemen:

     We are counsel to Immunex Corporation, a Washington corporation (the
"Company"). We have acted as counsel to the Company in connection with the sale
by the Company and American Home Products Corporation (the "Selling
Shareholder") of up to 70,000,000 shares (the "Shares") of the Company's common
stock, par value $.01 per share, and in connection with the preparation and
filing of a Registration Statement on Form S-3 (the "Registration Statement")
with the Securities and Exchange Commission under the Securities Act of 1933, as
amended (the "Securities Act").

     We have examined the Registration Statement and such instruments,
documents, and records which we deemed relevant and necessary for the basis of
this opinion, and we have also examined and relied upon representations,
statements or certificates of public officials and officers and representatives
of the Company. In such examination, we have assumed the following: (a) the
authenticity of original documents and the genuineness of all signatures; (b)
the conformity to the originals of all documents submitted to us as copies; and
(c) the truth, accuracy, and completeness of the information, representations,
and warranties contained in the records, documents, instruments, and
certificates we have reviewed.

     Based on such examination, we are of the opinion that upon the happening of
the following events:

     (a)  the effectiveness of the Registration Statement and any amendments
          thereto;

     (b)  due action by the Selling Shareholder authorizing the sale of the
          Shares owned by the Selling Shareholder;

     (c)  the offering and sale of the Shares as contemplated by the
          Registration Statement and in accordance with the Company's and the
          Selling Shareholder's actions authorizing the sale of the Shares; and
<PAGE>

     (d)  receipt by the Company and the Selling Shareholder of the
          consideration for the Shares, as contemplated by the Registration
          Statement;

the Shares will be duly authorized, validly issued, fully paid and
nonassessable.

     We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and any amendment thereto, and to the reference to our
firm in the prospectus of the Registration Statement under the heading "Validity
of Common Stock." In giving such consent, we do not thereby admit that we are
"experts" within the meaning of such term as used in the Securities Act, or the
rules and regulations of the Securities and Exchange Commission issued
thereunder, with respect to any part of the Registration Statement, including
this opinion as an exhibit or otherwise.

                                       Very truly yours,

                                       /s/ Orrick, Herrington & Sutcliffe LLP

                                       ORRICK, HERRINGTON & SUTCLIFFE LLP


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission